The Related Transcriptional Enhancer Factor-1 Isoform, TEAD4216, Can Repress Vascular Endothelial Growth Factor Expression in Mammalian Cells

Increased cellular production of vascular endothelial growth factor (VEGF) is responsible for the development and progression of multiple cancers and other neovascular conditions, and therapies targeting post-translational VEGF products are used in the treatment of these diseases. Development of methods to control and modify the transcription of the VEGF gene is an alternative approach that may have therapeutic potential. We have previously shown that isoforms of the transcriptional enhancer factor 1-related (TEAD4) protein can enhance the production of VEGF. In this study we describe a new TEAD4 isoform, TEAD4216, which represses VEGF promoter activity. The TEAD4216 isoform inhibits human VEGF promoter activity and does not require the presence of the hypoxia responsive element (HRE), which is the sequence critical to hypoxia inducible factor (HIF)-mediated effects. The TEAD4216 protein is localized to the cytoplasm, whereas the enhancer isoforms are found within the nucleus. The TEAD4216 isoform can competitively repress the stimulatory activity of the TEAD4434 and TEAD4148 enhancers. Synthesis of the native VEGF165 protein and cellular proliferation is suppressed by the TEAD4216 isoform. Mutational analysis indicates that nuclear or cytoplasmic localization of any isoform determines whether it acts as an enhancer or repressor, respectively. The TEAD4216 isoform appears to inhibit VEGF production independently of the HRE required activity by HIF, suggesting that this alternatively spliced isoform of TEAD4 may provide a novel approach to treat VEGF-dependent diseases.

[1]  J. Ambati,et al.  Mechanisms of Age-Related Macular Degeneration , 2012, Neuron.

[2]  T. Ye,et al.  Transcription factor TEAD4 regulates expression of Myogenin and the unfolded protein response genes during C2C12 cell differentiation , 2011, Cell Death and Differentiation.

[3]  S. Foo,et al.  RTEF-1, an Upstream Gene of Hypoxia-inducible Factor-1α, Accelerates Recovery from Ischemia* , 2011, The Journal of Biological Chemistry.

[4]  Matthew G. Crowson,et al.  IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression. , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  W. Hong,et al.  Structural basis of YAP recognition by TEAD4 in the hippo pathway. , 2010, Genes & development.

[6]  C. Sheridan,et al.  Expression of hypoxia-inducible factor−1α and −2α in human choroidal neovascular membranes , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[7]  M. Shibuya,et al.  VEGFR-1 Regulates Adult Olfactory Bulb Neurogenesis and Migration of Neural Progenitors in the Rostral Migratory Stream In Vivo , 2009, The Journal of Neuroscience.

[8]  M. Altaweel,et al.  Bevacizumab (Avastin) for the treatment of ocular disease. , 2009, Survey of ophthalmology.

[9]  K. Guan,et al.  The Hippo-YAP pathway: new connections between regulation of organ size and cancer. , 2008, Current opinion in cell biology.

[10]  Magali Saint-Geniez,et al.  Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors , 2008, PloS one.

[11]  D. Morris,et al.  Inhibitors of vascular endothelial growth factor in cancer. , 2008, Cardiovascular & hematological agents in medicinal chemistry.

[12]  Jiandie D. Lin,et al.  TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.

[13]  S. Kambhampati,et al.  VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis. , 2008, Biochemistry.

[14]  Zhengyu Zha,et al.  TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway , 2008, Molecular and Cellular Biology.

[15]  G. Feldmann,et al.  Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.

[16]  J. Rosenbaum,et al.  Identification of novel alternatively spliced isoforms of RTEF-1 within human ocular vascular endothelial cells and murine retina. , 2007, Investigative ophthalmology & visual science.

[17]  David T. Shima,et al.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. , 2007, The American journal of pathology.

[18]  Justine R. Smith,et al.  Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. , 2007, American journal of clinical pathology.

[19]  A. Adamis,et al.  Molecular biology of choroidal neovascularization. , 2006, Ophthalmology clinics of North America.

[20]  M. Yaffe,et al.  The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. , 2005, The Biochemical journal.

[21]  U. Thorgeirsson,et al.  VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms , 2005, Laboratory Investigation.

[22]  H. Kleinman,et al.  Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms , 2005, Oncogene.

[23]  P. Oettgen,et al.  RTEF-1, a Novel Transcriptional Stimulator of Vascular Endothelial Growth Factor in Hypoxic Endothelial Cells* , 2004, Journal of Biological Chemistry.

[24]  P. Carmeliet,et al.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model , 2004, Nature.

[25]  I. Cree,et al.  Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. , 2002, Archives of ophthalmology.

[26]  Joan W. Miller,et al.  Mechanism of age related macular degeneration , 2002 .

[27]  Christopher J. Lee,et al.  A genomic view of alternative splicing , 2002, Nature Genetics.

[28]  A. Ishida,et al.  Expression of vascular endothelial growth factor receptors in smooth muscle cells , 2001, Journal of cellular physiology.

[29]  M. DePamphilis,et al.  TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. , 2001, Genes & development.

[30]  R. Schwartz,et al.  Physical Interaction between the MADS Box of Serum Response Factor and the TEA/ATTS DNA-binding Domain of Transcription Enhancer Factor-1* , 2001, The Journal of Biological Chemistry.

[31]  Christopher J. Robinson,et al.  The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.

[32]  A. Wildeman,et al.  Tumor cell splice variants of the transcription factor TEF-1 induced by SV40 T-antigen transformation. , 2000, Biochimica et biophysica acta.

[33]  N. Eberhardt,et al.  Cooperative binding of TEF-1 to repeated GGAATG-related consensus elements with restricted spatial separation and orientation. , 2000, DNA and cell biology.

[34]  Ivana K. Kim,et al.  Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. , 1999, Investigative ophthalmology & visual science.

[35]  G. Lundborg,et al.  Vascular Endothelial Growth Factor Has Neurotrophic Activity and Stimulates Axonal Outgrowth, Enhancing Cell Survival and Schwann Cell Proliferation in the Peripheral Nervous System , 1999, The Journal of Neuroscience.

[36]  Hiroshi Yamamoto,et al.  Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[37]  P. Campochiaro,et al.  Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. , 1999, Investigative ophthalmology & visual science.

[38]  M. DePamphilis,et al.  Regulation of gene expression at the beginning of mammalian development and the TEAD family of transcription factors. , 1998, Developmental genetics.

[39]  N. Hay,et al.  Transcription enhancer factor 1 interacts with a basic helix-loop-helix zipper protein, Max, for positive regulation of cardiac alpha-myosin heavy-chain gene expression , 1997, Molecular and cellular biology.

[40]  L. Poellinger,et al.  Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  F. Malecaze,et al.  Overexpression of vascular endothelial growth factor induces cell transformation in cooperation with fibroblast growth factor 2 , 1997, Oncogene.

[42]  K. Suzuki,et al.  A novel family of TEA domain-containing transcription factors with distinct spatiotemporal expression patterns. , 1996, Biochemical and biophysical research communications.

[43]  S. Weremowicz,et al.  Cloning of human RTEF-1, a transcriptional enhancer factor-1-related gene preferentially expressed in skeletal muscle: evidence for an ancient multigene family. , 1996, Genomics.

[44]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[45]  Joan W. Miller,et al.  Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. , 1996, Investigative ophthalmology & visual science.

[46]  I. Farrance,et al.  The Role of Transcription Enhancer Factor-1 (TEF-1) Related Proteins in the Formation of M-CAT Binding Complexes in Muscle and Non-muscle Tissues (*) , 1996, The Journal of Biological Chemistry.

[47]  S. Izumo,et al.  cDNA Cloning and Characterization of Murine Transcriptional Enhancer Factor-1-related Protein 1, a Transcription Factor That Binds to the M-CAT Motif (*) , 1996, The Journal of Biological Chemistry.

[48]  J. Stone,et al.  Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.

[49]  S. Kourembanas,et al.  Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. , 1995, Circulation research.

[50]  M. Goldberg,et al.  Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.

[51]  Joan W. Miller,et al.  Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. , 1994, The American journal of pathology.

[52]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[53]  D. Connolly,et al.  Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.

[54]  D. Connolly,et al.  Human vascular permeability factor. Isolation from U937 cells. , 1989, The Journal of biological chemistry.

[55]  D. Connolly,et al.  Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. , 1989, The Journal of clinical investigation.

[56]  M. Streuli,et al.  Regulation of tissue‐specific alternative splicing: exon‐specific cis‐elements govern the splicing of leukocyte common antigen pre‐mRNA. , 1989, The EMBO journal.

[57]  J. Duker,et al.  Neovascularization of the optic disc associated with obstruction of the central retinal artery. , 1989, Ophthalmology.

[58]  B. Nadal-Ginard,et al.  Generation of protein isoform diversity by alternative splicing: mechanistic and biological implications. , 1987, Annual review of cell biology.